The Judicial Panel for Multidistrict Litigation transferred all existing Invokana (canagliflozin) and Invokamet (canagliflozin/metformin) cases alleging ketoacidosis and kidney disease from federal courts across the country to the United States District Court for the District of New Jersey on December 7, 2016. A total of 55 cases alleging injuries from these diabetes drugs were transferred from Illinois, Kentucky, Minnesota, Missouri, Virginia and West Virginia to a consolidated docket before the Honorable Brian R. Martinotti.

Invokana and Invokamet are classified as sodium-glucose-cotransporter-2 drugs (a/k/a SGLT2 inhibitors). SGLT2s work by preventing the kidneys from reabsorbing blood sugar. This lets the sugar leave the body through the urine, and thereby lowers blood glucose levels. SGLT2s are prescribed for Type 2 diabetes.… Read More


By Marilyn T. McGoldrick, Esq. Posted on June 17, 2013 On June 12, 2013, the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) transferred more than 39 Stryker Rejuvenate and ABGII defective hip cases to the U.S. District Court of Minnesota. The MDL was approved to allow for coordination of pretrial discovery and to preserve judicial… Read More